Is Cosmo Pharmaceuticals NV halal to invest in?

As of August 2026, Cosmo Pharmaceuticals NV COPN.VI is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Cosmo Pharmaceuticals NV a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Cosmo Pharmaceuticals NV using these criteria to determine its compliance status.

Can Muslims buy shares of Cosmo Pharmaceuticals NV?

Muslim investors may consider investing in Cosmo Pharmaceuticals NV if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Cosmo Pharmaceuticals NV classified as NOT HALAL?

Musaffa determines the Shariah status of Cosmo Pharmaceuticals NV by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Cosmo Pharmaceuticals NV updated?

The Shariah compliance status of Cosmo Pharmaceuticals NV may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Cosmo Pharmaceuticals NV become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Cosmo Pharmaceuticals NV?

You can check the latest Shariah compliance status of Cosmo Pharmaceuticals NV on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Cosmo Pharmaceuticals NV COPN.VI

Last Updated: Aug 12, 12:00 AM·WBAG

COPN.VI Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Cosmo Pharmaceuticals NV is classified as not halal.

NOT HALAL

Report Source: undefined Quarter Report

Cosmo Pharmaceuticals NV. Stock Analysis COPN.VI

Austria Health Care Small Cap

Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. The company is headquartered in Dublin, Dublin and currently employs 325 full-time employees. The company went IPO on 2016-05-18. The firm is focused on gastrointestinal (GI) diseases, dermatology, and healthtech. Its development pipeline includes Distal Ulcerative Colitis, Bile Acid Diarrhea, Solid Tumors, and AI Augmented Endoscopy. The firm's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, which is used for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which is used for the treatment of travelers’ diarrhea (TD); Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy, and Winlevi, which is used for the treatment of acne. The company also develops medical devices to assist with clinical decision-making.